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Tissue Engineering of Small Diameter Vascular Grafts
Omke E. Teebken and Axel Haverich
Leibniz Research Laboratories for Biotechnology & Artificial Organs, LEBAO, Thoracic & Cardiovascular Surgery,
Hannover Medical School, Hannover, Germany
Tissue engineering, using either polymer or biological based scaffolds, represents the newest approach to overcoming
limitations of small diameter prosthetic vascular grafts. Their disadvantages include thromboembolism and thrombosis,
anticoagulant related haemorrhage, compliance mismatch, neointimal hyperplasia, as well as aneurysm formation. This
current review represents an overview about previous and contemporary studies in the field of artificial vascular conduits
development regarding arterial and venous autografts, allografts, xenografts, alloplastic prostheses, and tissue engineering.
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Table 1. Characteristics and desirable features of the ideal vascular
graft.
Biocompatible
No healing disturbances
Non-toxic
Non-allergic
No induction of malignancies
Minimally traumatic to blood compounds
Non-thrombogenic
Resistant to infection
Compliant
Flexible, elastic, without kinking
Resistant to myointimal hyperplasia
Easy processing
Adequate physical and chemical properties, mechanical
durability
Readily available in a variety of sizes and lengths
No need for special storage or preparation procedures
Easy to suture
Eur J Vasc Endovasc Surg 23, 475±485 (2002)
doi:10.10 /ejvs.2002.1654, available online at http://www.idealibrary.com on53Introduction
Peripheral vascular disease (PVD) represents a grow-
ing health and socio-economic burden in most devel-
oped countries.1,2 Surgical bypass with vein remains
the majority of treatment.3,4 However, usable vein is
often absent.5,6
Expanded polytetrafluoroethylene (ePTFE) and
Dacron (polyethylene terephtalate fibre) are the most
widely used synthetic materials. Although successful
in large diameter (>5 mm) high-flow vessels, in low-
flow or smaller diameter sites they are compromised
by both thrombogenicity and compliance mismatch
(Tables 1 and 2).7,8 This review is based on previous
reviews and references about the topic and a Medline
search between the years 1966±2001 with the follow-
ing key words: small, vascular, and graft.
Results
Contemporary vascular grafts
Autografts
The use of venous and to some extent arterial auto-
grafts is well established in peripheral vascular sur-
gery.9,10 The results of grafting with other autologousPlease address all correspondence to: O. E. Teebken, Division of
Thoracic & Cardiovascular Surgery, OE 6210, Hannover Medical
School, Carl-Neuberg-Str. 1, D-30625 Hannover, Germany.
1078±5884/02/060475  11 $35.00/0 # 2002 Elsevier Science Ltd. Asources such as skin or dura were not encouraging
due to early thrombosis and aneurysm formation
(Table 3). In particular autografts from the small intes-
tine has shown some promise.11,12
Allografts
Fresh or cryopreserved arterial allografts are con-
sidered superior to artificial prostheses. They are
relatively resistant to infection, enjoy minimal
thromboembolic complications, and do not requireSterilisation (radiation)
Optional
Capable of local drug delivery
Low costs
ll rights reserved.
T
ab
le
2.
M
et
h
o
d
s
fo
r
b
lo
o
d
ty
p
es
v
es
se
l
re
p
la
ce
m
en
ts
.
A
u
to
g
ra
ft
A
ll
o
g
ra
ft
X
en
o
g
ra
ft
P
ro
st
h
es
is
V
ei
n
A
rt
er
y
D
if
fe
re
n
t
so
u
rc
es
D
if
fe
re
n
t
so
u
rc
es
P
la
st
ic
A
u
th
o
rs
C
ar
re
l
an
d
G
u
th
ri
e,
19
06
;9
0
G
o
y
an
es
,
19
06
;9
1
L
ex
er
,
19
07
;9
2
A
d
ru
s,
19
86
;5
T
ah
er
i,
19
87
9
3
Ja
b
o
u
la
y
an
d
B
ri
au
,
18
96
;9
4
F
ar
u
q
i,
20
00
9
5
C
ar
re
l,
19
08
;9
6
P
ir
o
v
an
o
,
19
11
;9
7
G
ro
ss
et
al
.,
19
47
;9
8
S
ch
u
lz
e
B
er
g
m
an
n
,
19
76
;1
7
D
ar
d
ik
,
19
76
;1
9
,9
9
S
h
ah
,
19
93
1
0
0
R
o
se
n
b
er
g
,
19
66
;2
3
C
la
rk
e,
20
01
7
7
V
o
o
rh
ee
s
et
al
.,
19
52
(V
in
io
n
N
);
1
0
1
E
d
w
ar
d
s,
19
57
(T
ef
lo
n
);
1
0
2
D
eB
ak
ey
,
19
60
(D
ac
ro
n
);
1
0
3
S
o
y
er
et
al
.,
19
72
;1
0
4
P
ar
o
d
i,
19
91
;1
0
5
M
ei
n
h
ar
d
(s
ee
d
ed
P
T
F
E
);
3
1
A
ld
en
h
o
ff
,
20
01
(P
o
ly
u
re
th
an
e)
;1
0
6
E
x
am
p
le
s
G
re
at
sa
p
h
en
o
u
s
v
ei
n
,
ar
m
v
ei
n
s,
p
o
p
li
te
al
v
ei
n
,
su
p
er
fi
ci
al
fe
m
o
ra
l
v
ei
n
In
te
rn
al
an
d
ex
te
rn
al
il
ia
c
ar
te
ry
,
su
p
er
fi
ci
al
fe
m
o
ra
l
ar
te
ry
,
in
te
rn
al
th
o
ra
ci
c
ar
te
ry
A
rt
er
y,
g
re
at
sa
p
h
en
o
u
s
v
ei
n
,
(D
ac
ro
n
±
ex
te
rn
al
ly
re
in
fo
rc
ed
)
u
m
b
il
ic
al
v
ei
n
,
cr
y
o
p
re
se
rv
ed
v
ei
n
se
g
m
en
ts
B
o
v
in
e
ca
ro
ti
d
/
in
te
rn
al
th
o
ra
ci
c
ar
te
ry
K
n
it
te
d
cr
im
p
ed
se
al
ed
D
ac
ro
n
;
ex
te
rn
al
ly
re
in
fo
rc
ed
ex
p
an
d
ed
P
T
F
E
A
v
ai
la
b
il
it
y
L
im
it
ed
;
d
ia
m
et
er
5
1
to
>
6
m
m
,
se
g
m
en
t
le
n
g
th
5
1
m
V
er
y
li
m
it
ed
;
d
ia
m
et
er
,
5
1
to
>
8
m
m
se
g
m
en
t
le
n
g
th
cm
L
im
it
ed
/
g
o
o
d
;
d
ia
m
et
er
4
±6
m
m
,
se
g
m
en
t
le
n
g
th
5
1
m
;
sp
ec
ia
l
st
o
ra
g
e
(e
.g
.
co
o
li
n
g
,
li
q
u
id
n
it
ro
g
en
)
G
o
o
d
;
d
ia
m
et
er
4±
8
m
m
,
se
g
m
en
t
le
n
g
th
5
40
cm
;
sp
ec
ia
l
st
o
ra
g
e
(e
.g
.
co
o
li
n
g
,
li
q
u
id
n
it
ro
g
en
)
V
er
y
g
o
o
d
;
d
ia
m
et
er
6
to
>
30
m
m
,
se
g
m
en
t
le
n
g
th
5
1
m
L
o
n
g
-t
er
m
re
su
lt
s
C
o
m
p
le
te
h
ea
li
n
g
,
d
eg
en
er
at
io
n
an
d
an
eu
ry
sm
s
ar
e
ra
re
,
in
ti
m
a
h
y
p
er
p
la
si
a
V
er
y
g
o
o
d
N
o
co
m
p
le
te
h
ea
li
n
g
,
d
eg
en
er
at
iv
e
d
is
ea
se
;
ca
lc
if
ic
at
io
n
s
(D
ac
ro
n
re
in
fo
rc
em
en
t!
);
1
0
7
±
1
0
9
tr
an
sm
is
si
o
n
o
f
d
is
ea
se
D
eg
en
er
at
io
n
,
ca
lc
if
ic
at
io
n
,
in
ti
m
a
h
y
p
er
p
la
si
a;
tr
an
sm
is
si
o
n
o
f
d
is
ea
se
(?
)
±
P
E
R
V
,
B
S
E
In
ti
m
al
h
y
p
er
p
la
si
a,
th
ro
m
b
o
si
s,
o
b
st
ru
ct
io
n
,
su
tu
re
an
eu
ry
sm
s
5-
y
ea
r
p
at
en
cy
9
,1
1
0

75
%
(g
re
at
sa
p
h
en
o
u
s
v
ei
n
);

65
%
(a
rm
v
ei
n
s)

95
%

60
%
(u
m
b
il
ic
al
v
ei
n
)

59
%
(b
o
v
in
e
x
en
o
g
ra
ft
s)

40
%
(P
T
F
E
);

80
%
(E
C
se
ed
ed
P
T
F
E
)
C
o
m
p
li
an
ce
m
is
m
at
ch


(
)
(
)
ÿ
B
io
co
m
p
at
ib
il
it
y


(
)


H
an
d
li
n
g
ÿ
(p
re
p
ar
at
io
n
,
ad
d
it
io
n
al
w
o
u
n
d
co
m
p
li
ca
ti
o
n
s)
ÿ
(p
re
p
ar
at
io
n
,
ad
d
it
io
n
al
w
o
u
n
d
co
m
p
li
ca
ti
o
n
s)
(
)
(
)

C
o
st
s


ÿ,

25
00
E
u
ro
ÿ,

30
00
E
u
ro
(
),
50
0±
15
00
E
u
ro
L
eg
en
d
:
fa
v
o
u
ra
b
le
;
le
ss
fa
v
o
u
ra
b
le
(
);
u
n
fa
v
o
u
ra
b
le
ÿ;
n
o
t
av
ai
la
b
le
/
;
P
E
R
V

p
o
rc
in
e
en
d
o
g
en
o
u
s
re
tr
o
v
ir
u
s;
B
S
E

b
o
v
in
e
sp
o
n
g
if
o
rm
en
ce
p
h
al
it
is
.
476 O. E. Teebken and A. Haverich
Eur J Vasc Endovasc Surg Vol 23, June 2002
Table 3. Autogenous arterial replacements with tissue of non-vessel origin.
Material Reference Origin Implantation site Results
Pericardium Sako et al., 1951,
1962111,112
Pericardium Dog aorta 24/40 dogs survived,
graft dilatation
Zech et al., 1955113 Pericardium Pig aorta 10 pigs, dilatations
ruptures
Love, 1998114 Pericardium, stent enhanced,
no kinking
Cattle carotid artery 100% patency after
5 months
Cutis Harton, 1956115 Skin of breast and abdomen Dog aorta High rate of
thrombosis
especially when
epithelium was the
inner portion, lower
when subcutis was
inside
Pratt, 1958116 Skin of breast and
abdomen
Dog aorta 10/10 dogs died from
rupture or thrombosis
within max. 52 days
Wagner, 1958117,118 Skin was removed with a
dermatom and was
bathed in heparin
Human, aortofemoral,2
femoropopliteal,1
axillobrachial1 bypass
Patent within the
observation period
of 12±14 months
Fascia Peirce, 1953119 Anterior portion of
M. rectus abdominis
Dog aorta 8/10 dogs survived,
5 dilatations
Fascia Tsukagoshi, 1999120 Fascia-wrapped
fibrocollagenous tube
Rabbit 11 from 15 grafts
patent
Fascia and
peritoneum
Vollmar, 1960121 Aponeurosis of M. rectus
abdominis and
peritoneum
Dog aorta 30 dogs, thrombi in
40%, autologous
blood incubation
lowers the rate,
dilatation within
1 year
Small
intestine
Pratt, 1958116 Small intestine (peritoneal
part as the lumen)
Dog 14/14 dogs died
within 14 days
from thrombus
or rupture
SzoÈlloÈssy, 1958122 Small intestine (peritoneal
part as the lumen)
Dog 5/5 dogs died within
10 days from
thrombus or
rupture
Lantz et al., 1990123 Small intestinal submucosa
(cell free collagen)
Dog (carotid and
femoral position)
36 grafts, 2 ruptures,
5 occlusions within
21 days after surgery,
1 occlusion within
14 weeks, 4 aneurysmal
dilation
Lantz et al., 1993
(review)124
Small intestinal submucosa
(cell free collagen)
Dog Complete endothelialisation
after 28 days, follow-up
periods of up to 5 years
found no evidence of
infection, intimal
hyperplasia, or
aneurysmal dilation
Huynh et al., 1999125 Small intestinal submucosa
combined with bovine collagen
Rabbit Patent grafts, remodeling
into cellularised vessels,
exhibiting physiological
responses to vasoactive
agents
Roeder, 200112 Small intestinal submucosa
(cell free collagen)
Dog (carotid artery) 7 grafts, no obstruction
after 55±63 days
Muscle and
peritoneum
SzoÈlloÈssy, 1958122 Transverse muscle and
parietal peritoneum
Dog 17 dogs, 9 insufficiencies,
1 thrombosis, only 3 dogs
survived max. 184 days
Horneffer, 1988126 Skeletal muscle (vascularised
and devascularised flaps)
Swine (patch or 2 cm
segment of the
descending aorta)
8 vascularised patches: no
stenosis, no aneurysms after
16 month; devascularised
muscle: 3/7 suture line
dehiscence within 2 weeks
Tissue Engineering of Small Diameter Vascular Grafts 477
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Table 3. Continued.
Material Reference Origin Implantation site Results
Ureter Levin, 1907/8127 Ureter, cooked Dog Not successful
Uematsu, 1998128 Ureter, crosslinked Rabbit carotid artery 6/6 after 1 month
6/6 after 6 month
Diaphragm Wesolowski, 1962129 Diaphragm Pig (thoracic aorta) Successful
Subcutis Schilling, 1964130 Forming of collagen tubes
on subcutaneous implanted
mesh scaffolds,
re-implantation after
removement of scaffold
Dog aorta Successful, no dilatation
after 3 years
Cutis Inoue et al., 1996131 Human acellular dermal
(ACD) matrix
Rat femoral artery
interposition model
90% patency (9/10) patent
after 28 days, 6 false
aneurysms
Various tissues Clarke et al., 200177 Bovine acellular matrix Dog aorta 100% patent after 10 month,
no aneurysms
Vein, allogenic Lamm et al., 2001132 Human allograft,
cryopreserved, seeded
with autologous EC
Human, CABG 15 grafts, 1 pt. died, 2 occluded
Artery, xenogenic,
decellularised
Kaushal et al., 200175 Porcine decellularised
iliac artery, seeded with
vascular precursor cells
Ovine, carotid interposition
graft 4 mm i.d.
Seeded grafts remained patent for
130 days, unseeded grafts were
occluded after 15 days
Artery, allogenic,
decellularised
Malone et al., 1984133 Dog, artery, detergent,
cross-linked
and non cross-linked
Dog, carotid interposition Overall graft patency was 80%,
endothelial coverage only in the
non-crosslinked group
Artery, allogenic,
decellularised
Teebken et al., 200150 Porcine decellularised
carotid artery, seeded
with EC cells
Porcine carotid artery 71% patency after 4 month
Artery, allogenic,
decellularised
Ostapczuk et al., 1998134 Porcine, internal mammary
artery
Cattle, carotid 4/5 were occluded after 103 days,
1 animal died
Grafts grown in
the peritoneal
cavity
Campbell et al., 1999135 Collagen grafts with an
inner mesothelial
layer grown in the
peritoneal cavity
Rat aorta, rabbit carotid
artery
Feasible
478 O. E. Teebken and A. Haverichanticoagulation.13,14 Limitations include their limited
availability and durability due to calcification, aneur-
ysmal dilation, and rupture.15,16 Allogenic vein
grafts17,18 or human umbilical cord veins19,20 have
also been used. In various studies, equal patency
rates to PTFE were documented (Table 2). Additional
quality can be obtained by seeding the vein with
autologous cells.21 The use of immunosuppression
to enhance graft patency by reduction of inflam-
matory reaction and thrombogenicity remains
controversial.15,22
Xenografts
Norman Rosenberg developed arteries derived from
bovine sources in 1963 (Table 2).23 However, long-term
results were not encouraging, due to aneurysm forma-
tion (3±29%), infection (3±6%), and a high incidence
of thrombosis.24±25 The antigenicity has a deleterious
effect on subsequent endothelialisation.26 For these
reasons use of xenografts cannot be recommended
for peripheral vascular reconstruction.28Eur J Vasc Endovasc Surg Vol 23, June 2002Artificial prostheses and endothelial cell seeding
Although successful in large calibre, high flow
vessels, prosthetic grafts deliver disappointing results
in small, low-flow vessels.29±31 Numerous modifica-
tions and techniques to enhance patency have been
evaluated both in vitro and in vivo. These include
chemical modifications, coating32,33 and seeding of
the surface with endothelial cells,34,35 myofibroblasts,
or mesothelial cells.36 In vitro endothelialisation of
ePTFE grafts may result in a patency rate for (periph-
eral) arterial prostheses that is comparable to that of
vein grafts.35,38
Biodegradable polymers
Polyglycolic acid, polydioxanone, and polylactide are
FDA approved and therefore the preferred material
for bioresorbable grafts.39 The first fully resorbable
Vicryl graft (a polyglycolic acid and polylactide) was
prone to complications including aneurysms and rup-
ture.40 Subsequently, Greisler and colleagues studied
Tissue Engineering of Small Diameter Vascular Grafts 479the morphological and functional characteristics of
tissue reactions to such prostheses.41 Forty-two
woven polyglactin 910/polypropylene prostheses
(24 4 mm internal diameter) implanted into infra-
renal aortas were harvested after 2 weeks to
12 months. Results showed 100% patency, absence of
aneurysms, and an incidence of 2% stenoses. Conflu-
ent endothelial-like cellular luminal surfaces covering
oriented smooth muscle-like myofibroblasts com-
prised the inner capsules, which stabilised in thick-
ness at 1±2 months. Compliance studies reflected
a 0.65 mm (14%) change over a pressure range of
0±160 mmHg. All regenerated prosthesis-tissue com-
pounds had bursting strengths greater than the
proximal perianastomotic native aortas (600 and
2000 mmHg). In addition, Greisler and colleagues
showed that transanastomotic pannus ingrowth as
found in Dacron grafts is not the primary source of
cells replacing absorbable vascular prostheses.42±45
Tissue ingrowth leads to changes in the biomechan-
ical properties of a vascular graft.42 The phago-
cytosis of biomaterials can lead to activation of
macrophages. Activated macrophages stimulate a
variety of growth factors including PDGF, FGF, TGF
beta, and TNF.43 Vascularisation by the host is stimu-
lated for example by the pore size of the graft. Above a
minimal pore size, vascularization is stimulated.
Below this `` critical porosity size'' an inflammatory
reaction is initiated by the graft. This critical pore
size depends on the kind of material (cellulose acetate:
0.8 mm; mixed esters cellulose: 1.2 mm; PTFE: 1.0 mm;
acrylic copolymer: 0.8 mm).46 Galetti, studying fully
resorbable polyglactid prostheses coated with differ-
ent polymers, demonstrated that polymer compos-
ition clearly influences the repair process.47,48 Both,
the induction of severe foreign body reaction by bio-
degradable polymers (especially if not completely
degraded at the time of implantation) and polymer
surface thrombogenicity49 can cause graft failure. In
contrast to promising results in rodents and dogs, data
indicate that polydioxanone prostheses are not suit-
able for grafting blood vessels of an inner diameter of
4 mm, at least in a porcine model.50 Further research
concentrates on the adjustment of biophysical proper-
ties of current substances to facilitate complete in vitro
integration of these devices.51 Manipulation of the
wound healing process and the manner in which
tissues interact with inert biomaterials were both
made possible with the discovery of the RGD (argin-
ine-glycine-aspartate) sequence as a major cell recog-
nition signal within the extracellular matrix.52,53
However, so far there is no completely biodegradable
small diameter graft suitable for the arterial circu-
lation in humans.The `` tissue engineering'' approach
A blood vessel made of autologous cells and a bio-
compatible scaffold with the potential to remodel,
repair, and grow would be a major therapeutic
advance. Tissue engineering procedures could lead
to completely biological vascular grafts with good
handling qualities and sufficient burst strength. The
aim to produce a truly stable artificial blood vessel
containing no synthetic material,8,54,55 requires inva-
sion and ingrowth of smooth muscle cells as well as
fibroblasts into the scaffold. This can be achieved
either in vivo from the adjacent tissue or circulating
cells after implantation, or in vitro by means of culti-
vated cells. Such graft should not induce substantial
inflammatory reactions that could either damage its
wall, setting the scene for long term aneurysm forma-
tion or trigger acute thrombosis (Table 1). The degree
of graft remodelling and cell replacement by host
tissue is of great importance. Premature loss of
implanted cells through turnover and remodelling
by the host would be detrimental. Furthermore,
long-term durability with freedom from both calcifi-
cation and excessive tissue overgrowth must be
shown in animal experiments.
Cell seeding of biodegradable scaffolds
Cell seeding of tubular biodegradable structures is
well described.7,56,57 Kim et al. showed that the pheno-
type of smooth muscle cells in engineered tissues and
the composition of newly expressed matrix proteins
are strongly influenced by the scaffold on which they
were seeded.58 Binding to the scaffold via various
integrins may cause differential gene expression in
these cells.
The combination of a biodegradable polymer with
biological materials to create a kind of composite-
matrix may actually combine the advantages of both
materials. Polymers give stability and can be used
in a predefined form. Biological materials contain
sequences of amino acids, e.g. RGD-peptide, YIGSR
(Tyr-Ile-Gly-Ser-Arg), or REDV (Arg-Glu-Asp-Val)
influencing the differentiation of cells.59,60 The gel
can also function as a kind of delivery system for
added biologically active substances such as growth
factors (e.g. vascular endothelial growth factor, basic
fibroblast growth factor)61 which can additionally
modulate the differentiation of the seeded cells
(Table 1). The modulation of differentiation of seeded
cells to a functional phenotype has become a major
aim in current studies.62 The selective choice of
ingredients of the gel and additives to the gel promise
the ability to influence differentiation in a certainEur J Vasc Endovasc Surg Vol 23, June 2002
480 O. E. Teebken and A. Haverichdirection. Endothelial cells can differentiate into a
functional phenotype in vivo.63 Further investigations
have to ensure the preservation of important endothe-
lial functions such as antithrombogenicity in such
constructs in vitro and in vivo.
Biological scaffolds
A different approach to tissue engineering of vascular
grafts includes the use of decellularised matrices, as
initially introduced by Rosenberg.23 Theoretically, the
absence of synthetic material should allow for com-
plete graft integration into the organism and provide a
truly stable artificial blood vessel long-term. The acel-
lular matrix gradually transforms from an allograft to
an implant of primarily autogenous, self-renewing
and living tissue. This process requires in vivo inva-
sion and ingrowth of smooth muscle cells and fibro-
blasts into the acellular matrix scaffold from the
adjacent tissue after implantation. The extracellular
matrix is a complex aggregate of glycoproteinsFig. 1. Well preserved collagen fibres in a porcine carotid artery after e
Magnification 1150; (b) Scanning electron micrograph of the lumina
Eur J Vasc Endovasc Surg Vol 23, June 2002composed of a number of different macromolecules
whose structural integrity and functional composition
are important in maintaining normal tissue architec-
ture, in development, and in tissue function.64±68
Histological examination of decellularised carotid
arteries revealed well preserved, normally arranged
fibular collagen and elastin fibres (Fig. 1).69±71 These
structural matrix proteins provide an acellular scaf-
fold, which can be successfully repopulated with auto-
logous cells in vitro prior to implantation. Such scaffolds
have also been shown to be repopulated in vivo (Fig. 2).
Due to the removal of cellular antigens, especially
foreign endothelial cell antigens, the reduced immu-
nological potential may prevent the graft from critical
inflammatory or immune reactions.50,63,69 One goal in
transplantation of porcine tissue to man is to diminish
the expression of the most important xenoantigen, the
1±3 alpha galactosyl epitope,72 responsible for hyper-
acute rejection. Furthermore, repopulation of xeno-
grafts with human autologous cells in vitro to enhance
graft survival is an active field of research (Tablenzyme decellularisation. (a) Cross section. Hematoxylin eosin stain.
l surface. Magnification 1 2000.
Fig. 2. (a) Macroscopic view of an unseeded decellularised carotid graft 6 weeks after implantation. Perianastomotic endothelialisation
(asterisks) and thrombi (arrows) in the middle portion. (b) Endothelial cell seeded decellularised graft. Factor VIII and hematoxylin eosin
stain. Endothelial cells on the luminal surface and myofibroblasts in the vessel wall (arrows). Magnification 1150.
Tissue Engineering of Small Diameter Vascular Grafts 4813).37,71,73,74 However, the sharp distinction between
seeded and unseeded decellularised grafts (seeded
100% patency, unseeded: 100% obstruction) as found
by Kaushal et al. in a dog model remains an excep-
tion.75 Nonetheless, this is the first report of tissue
engineering a vascular graft utilising endothelial pre-
cursor cells. Recently, Goldstein and colleagues as well
as Clarke and co-workers presented their experimen-
tal and clinical results including small calibre bypass
grafts (Table 3).76,77
In 1979 Jones published a concept for constructing a
blood vessel wall by growing cattle endothelial cells on
a preformed layer of rat smooth muscle cells.78 Final
cell density was more than two-fold higher than on
plastic. Electron microscopy showed the existence of a
basal lamina-like structure between the two cell types.
Weinberg and co-workers were the first to describe
a technique to grow bovine aortic cells in collagen
lattices.79,80 Endothelial cells on the luminal surface
and smooth muscle cells in the wall were welldifferentiated. Endothelial cell lining functioned
physically, as a permeability barrier, producing von
Willebrand's factor and prostacyclin. However, the
model was not stable for itself, but its strength
depended on its multiple layers of collagen and an
integrated polyester mesh.
Matsuda et al. presented another method of vascu-
lar wall reconstruction using a compliant but non-
degradable artificial graft as a scaffold. The vessel
wall showed a four-layered structure. Monolayered
endothelial cells (`` biomimic'' intima), an artificial
basal membrane, a media composed of smooth muscle
cells embedded in collagen fibre nets, and an open-cell
structured microporous compliant artificial graft as a
structural matrix.81
Exclusively autologous approaches
The group of Robert Langer and the Vacanti brothers
extended such experiments by developing a model ofEur J Vasc Endovasc Surg Vol 23, June 2002
482 O. E. Teebken and A. Haverichthe arterial wall involving co-cultures of endothelial
cells and smooth muscle cells.82 L'Heureux and co-
workers reported a novel approach to tissue-engi-
neered blood vessel based exclusively on the use of
cultured human cells, i.e. without any synthetic or
exogenous biomaterials.83 A cohesive sheet made
from cultured human smooth muscle cells was placed
around a tubular support to produce the media of the
vessel. A similar sheet of human fibroblasts was
wrapped around the media to provide an adventitial
layer. After maturation, the tubular support was
removed and endothelial cells were seeded on the
luminal surface. This technique resulted in a well-
defined, three-layered organisation and production
of extracellular matrix proteins, including elastin.
Smooth muscle cells re-expressed desmin, a differen-
tiation marker known to be lost under standard cul-
ture conditions. The endothelium expressed von
Willebrand factor, incorporated acetylated LDL, pro-
duced PGI2, and strongly inhibited platelet adhesion
in vitro. This paper is the first report of a completely
biological tissue-engineered blood vessel to display a
burst strength comparable to that of human vessels
(>2000 mmHg). Short-term grafting experiments in a
canine model demonstrated good handling character-
istics. Recently, Niklason et al. reported the tissue
engineering of functional arteries in vitro with com-
parable rupture strengths.62,84 However, clinical data
does not exist.
Conclusions and Outlook
Tissue engineering is a rapidly expanding field and
represents the newest concept in order to alleviate the
limitations of small diameter prosthetic vascular
grafts. Techniques are being developed for culturing
a variety of tissues both in vitro and in vivo using
polymer or biological scaffolds to support tissue
growth. These scaffolds are generally biodegradable
and often involve compounds already approved for
human implantation. In some cases, these polymers
may be chemically modified to exhibit selective cell
adhesion properties, which enhance cell attachment
and subsequent tissue growth. One of the prime tar-
gets of tissue engineering involves development of
small calibre vascular grafts, due to the lack of
adequate substitutes in a variety of clinical situations.
Therefore, tissue engineering holds the potential for
the in vitro development of autologous or allogenic
transplantable vascular conduits. While autologous
venous or arterial vessels are generally used, not all
patients possess adequate conduits for revascularisa-
tion. In consequence, different types of tubularEur J Vasc Endovasc Surg Vol 23, June 2002scaffolds have been specially designed for culturing
small calibre arteries in vitro. However, many factors
of influence remain unclear. For example, the exact
role of mechanical stress in regard to cell differenti-
ation has to be defined in future experiments.85
Manipulation of cell adhesion has to remain an active
field of research.86 Also, in addition to currently
initiated endothelial cell sources, the optimal origin
of autologous endothelial cells needs to be defined.
In most preparations, venous endothelial cells were
the cell type of choice for tissue engineering (probably
because of simple harvesting procedures),87 but other
cell types have been used successfully as well.88 On
the other hand one should be cautious in the taking of
all kinds of endothelial cells, especially e.g. in aged or
diabetic people.89 Tiwari and colleagues emphasised
in their recent review that standard models have to be
defined to allow for answering all questions such as
thrombogenicity, durability, biocompatibility, and
comparison between different groups of researchers.6
This review shows that there are two main fields of
research in tissue engineering. One is based on cell
seeding of synthetic polymers. Except for seeding of
small calibre PTFE prostheses, most published data
describes in vitro testing of those devices. Animal
studies have been successfully conducted with bio-
degradable grafts as well, but no paper reports on
implantations in humans. On the other hand, only
biological scaffolds either seeded or unseeded, have
been successfully used in the arterial circulation
clinically.76,77 It seems that this kind of implant, either
based on a xenogenic or on an allogenic decellularised
matrix will be used even more frequent in the near
future until adequate synthetic devices will have been
developed.
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